This confirm our previous reports which indicate that high AR levels respect to ER levels may help to identify and treat a specific subgroup of ER+ patients (luminal BC) having tumors with unfavorable clinical and molecular characteristics [90,136]. This evidence concerns the gene ESR1 and breast cancer.